In Silico Innovation in Drug Discovery and Development

In Silico Biolabs is revolutionizing the drug discovery and development process through cutting-edge computational technologies. Our mission is to significantly reduce the time and resources required in early-stage drug development and the production of industrially important compounds, enabling more efficient and cost-effective research and manufacturing. By leveraging the power of advanced algorithms and data-driven insights, we help our partners identify promising drug candidates, optimize production pathways for target molecules, and make more informed decisions earlier in the development process. Our innovative platform combines sophisticated metabolic pathway analysis with predictive modeling capabilities, offering a comprehensive solution for both pharmaceutical and industrial biotechnology applications. This unique approach allows us to address complex challenges in drug discovery and the synthesis of high-value chemicals, potentially transforming the way drugs and industrial compounds are brought to market.

a bunch of lights that are hanging from a ceiling

Partner with us

About us

Based in Albuquerque, New Mexico, In Silico Biolabs has developed innovative software that turns computer-based predictions into practical solutions for drug discovery and industrial biotechnology. Our unique platform combines metabolic pathway analysis with drug candidate evaluation, streamlining the process of developing new pharmaceuticals and industrial compounds.

We work with a range of partners, from startups to established pharmaceutical companies and biotechnology firms, providing insights that accelerate drug discovery and optimize production processes. By integrating biological and chemical analyses, we offer a comprehensive view of drug candidates and their production pathways. At In Silico Biolabs, we're dedicated to making drug discovery and industrial compound production faster, more efficient, and more cost-effective for our partners in the life sciences industry.

At In Silico Biolabs, we are developing a cutting-edge software tool designed to revolutionize metabolic engineering. Our innovative platform efficiently identifies optimal and sub-optimal pathways for biological, chemical, and hybrid production of target compounds. This advanced algorithm surpasses current tools by providing a user-friendly interface, incorporating proprietary reactions, and offering clear pathway visualizations. The software's unique ability to rank pathways based on maximum theoretical yield, calculated through flux balance analysis, empowers researchers to make informed decisions in synthetic biology. By streamlining the complex process of pathway identification, our tool accelerates the development of novel bio-based products, positioning us at the forefront of computational biotechnology.

Advancing Metabolic Engineering with Innovative Pathway Discovery Software

Partner with us

Physiologically-based pharmacokinetic (PBPK) modeling plays a pivotal role in drug research and development— These models employ equations to precisely calculate the distribution of a drug throughout the body. Leveraging available scientific data and factors, we can predict how drugs will be absorbed, distributed, metabolized, and excreted. PBPK modeling proves invaluable in optimizing drug dosing, forecasting potential drug interactions, and evaluating the safety and efficacy of novel medicines. Recognizing its significance, the US FDA has acknowledged the value of PBPK modeling, providing guidelines for its integration into drug approval processes.

PBPK modeling

Custom Model Development

We understand the nuances of M&S (modeling and simulation) work such as parameter identification. We help build models for our clients from the ground up. We recognize that complex formulations require custom models. Commercially available software packages may not accommodate your innovations. Whether you are interested in utilizing M&S to support regulatory submissions or to elucidate and enhance your understanding of your formulations' pharmacokinetic dispositions, we can help. Our methods allow us to not only develop models for our clients from the ground up, but also to help their internal teams to easily access and work with these models.

ADMET for Drug Screening

ADMET plays a pivotal role in the success of drug candidates. Approximately 50% of drug candidates fail due to efficacy issues, and up to 40% fail due to toxicity concerns. In Silico Biolabs utilizes advanced in-silico ADMET studies, employing computer simulations and modeling to predict how a compound will behave in the body. This innovative approach provides an alternative to traditional in vivo testing, allowing drug developers to assess the viability of a candidate early in the process. Our in-silico ADMET services empower developers to make informed go-no-go decisions, optimizing the selection of drug candidates for late-stage preclinical and clinical programs. Stay ahead in drug discovery with In Silico Biolabs – where science meets simulation for safer and more efficient pharmaceutical development.

Standalone Tool

In addition to developing personalized PBPK models for your innovative projects, we offer specialized services that include the creation of an executable file that is not dependent on any commercial software platform. This file allows you and your team to easily comprehend, educate, and share knowledge within your department. With this independent executable file, you can gain a deeper understanding of the models created, effectively teach others, and seamlessly transfer valuable information. It is our aim to provide comprehensive solutions that empower you and your team to make informed decisions and drive progress within your organization.

Services

Contact us

Email

Phone

partner@insilicobiolabs.com

505-803-4865